Please wait a minute...
European Journal of Gynaecological Oncology  2018, Vol. 39 Issue (6): 997-1001    DOI: 10.12892/ejgo4306.2018
Original Research Previous articles | Next articles
Carboplatin and low-dose paclitaxel. An effective regimen in older and comorbid patients with advanced cervical cancer. A phase II study
J. Coronel1, 2, D. Cantú 1, M. RodrÍguez-Morales1, L. Cetina1, A. González-Fierro3, A. Dueñas-González3, *()
1 Division of Clinical Research, National Cancer Institute, Mexico City, Mexico
2 Department of Medical Oncology, Regional Hospital “Adolfo López Mateos” ISSSTE, Mexico City, Mexico
3 Division of Basic Research, National Cancer Institute, Mexico City, Mexico
Download:  PDF(172KB)  ( 77 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: To investigate the efficacy and safety of low-dose weekly paclitaxel and carboplatin in elderly and/or any age comorbid patients with FIGO Stage IVB, recurrent or persistent cervical cancer. Materials and Methods: Thirty patients were accrued. Eligibility criteria included older than 65 years, or any age with uncontrolled diabetes and/or blood hypertension and other comorbid conditions. Treatment consisted of six 28-day cycles of carboplatin at AUC of 5 at day 1, and low-dose paclitaxel at 50 mg/m2 at days 1, 8, and 15 infused in two hours. Metabolic response was evaluated by [18F]-FDG uptake (PET-CT) and toxicity with the NCI CTC v2. Results: From January 2012 to January 2015 a total of 30 patients were included in the study. The median number of chemotherapy cycles administered was five (1-6). Three (10%) had complete response and nine (30%) partial response for an overall response rate of 48%. One patient (4%) had stable disease and 17 (56%) showed progressive disease. At a median follow-up time of 12.5 (1-37) months, the median progression-free survival (PFS) and overall survival (OS) were 7.7 and 14.3 months, respectively. Grade 4 toxicities were anemia in three patients (10%), grade 3 neutropenia and vomiting occurred in one (3%), and one (3%) respectively. All other toxicities were grades 1 and 2. A substantial proportion of patients had grade zero toxicity. Conclusion: This study shows that this 28-day regimen of low-dose carboplatin and paclitaxel is effective and safe in an elderly and/or comorbid population of advanced cervical cancer.
Key words:  Advanced cervical cancer      First-line chemotherapy      Low-dose paclitaxel      Carboplatin      Aged      Comorbid     
Published:  10 December 2018     
*Corresponding Author(s):  A. Dueñas-González     E-mail:  alfonso_duenasg@yahoo.com

Cite this article: 

J. Coronel, D. Cantú, M. RodrÍguez-Morales, L. Cetina, A. González-Fierro, A. Dueñas-González. Carboplatin and low-dose paclitaxel. An effective regimen in older and comorbid patients with advanced cervical cancer. A phase II study. European Journal of Gynaecological Oncology, 2018, 39(6): 997-1001.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4306.2018     OR     https://ejgo.imrpress.com/EN/Y2018/V39/I6/997

[1] Kelly Baillie, Nicholas Reed, Jennifer Laskey, Jiafeng Pan, Kimberley Kavanagh, Marion Bennie, Christine Crearie, Tanja Mueller, Azmat Sadozye, Rosie Harrand, Ashleigh Kerr, Kathryn Graham. Neoadjuvant chemotherapy in locally advanced cervical cancer: real-world data from the Cancer Medicines Outcomes Programme (CMOP)[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 926-935.
[2] Jing Fang, Jinmei Fang, Ailin Wu, Yufei Zhao, Yun Liu. Clinical analysis of predisposing factors for radiation enteritis in patients with cervical cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 951-956.
[3] Agnieszka Lewandowska, Lukasz Wicherek, Krzysztof Koper, Sebastian Szubert, Joanna Terlikiewicz, Grzegorz Panek, Marlena Cwynar, Andrzej Roszak, Zaneta Warenczak-Florczak. An analysis of outcomes of patients with locally advanced cervical cancer treated by emergency hysterectomy due to vaginal hemorrhage followed by chemoradiation and surgery in cases of locally advanced cervical cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 682-687.
[4] Jessé L. da Silva, Lucas Z. de Albuquerque, Ana L. Gasparotto, Beatriz R. L.de Aguiar, Darlyane de S.B. Rodrigues, Ticiane C. Farias, Eduardo Paulino, Andreia C. de Melo. Efficacy and safety of carboplatin plus paclitaxel in gynecological carcinosarcoma: a Brazilian retrospective study[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 512-520.
[5] Mirjana Rajer, Brigita Gregoric, Milanka Zivanovic, Erik Skof. Cutaneous leukocytoclastic vasculitis in a patient treated with carboplatin for uterine carcinoma[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 165-167.
[6] Lindsey Buckingham, Lori Cory, Colleen Brensinger, Xiaochen Zhang, Robert A. Burger, Fiona Simpkins, Emily M. Ko. Epidemiologic profile of benign versus oncologic gynecology populations: similar procedures, different patients[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 396-401.
[7] J.J. Noh, H. Jung, C.H. Choi. Mesonephric adenocarcinoma treated with paclitaxel-carboplatin adjuvant chemotherapy: a case report[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 679-683.
[8] Lili Qian, Zhen Shen, Xuefen Zhang, Dabao Wu, Ying Zhou. Fertility-sparing management for bulky cervical cancer with systemic chemotherapy and conization: a case report and review of the literature[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 684-687.
[9] G.-L. Zhang, C.-X. Ba, A.-Y. Liu, D.-Q. Ren, H. Li, J.-J. Zhu, J.-N. Fan, P.-L. Zhang. Investigation of paclitaxel-carboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab in HER2-positive breast cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 899-902.
[10] Kaijia Tu, Cai Chen, Xiaoxiao Cheng, Longyu Li. Comparison of the curative effect and safety of consolidation chemotherapy after concurrent chemoradiotherapy with concurrent chemoradiotherapy alone for locally advanced cervical cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 558-563.
[11] K. Chikazawa, S. Netsu, R. Konno, S. Motomatsu. Concurrent external beam pelvic radiotherapy and weekly paclitaxel/carboplatin therapy followed by hysterectomy improves prognosis and survival of patients with non-squamous cell carcinoma of the cervix[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 860-866.
[12] W. Kudaka, T. Nakasone, Y. Arakaki, T. Nakamoto, A. Wakayama, Y. Kinjyo, Y. Taira, Y. Nagai, I. Kaneshima, K. Nishihira, Y. Aoki. Adjuvant docetaxel and carboplatin chemotherapy for patients with high-intermediate and high-risk endometrial cancer[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 917-920.
[13] Chao Yang, Juan Tan, Chang-chun Li, Jun Zhang, Xiang-ru Kong, Zhenzhen Zhao, Xiao-bin Deng, Liang Peng, Shan Wang. Fatal overdosage with cisplatin by accidental substitution for carboplatin: a case report and literature review[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 981-984.
[14] D. Nakayama, H. Nishi, R. Kato, Y. Sagawa, F. Terauchi, K. Isaka. Biweekly administration of docetaxel and carboplatin for advanced or recurrent endometrial and ovarian carcinomas[J]. European Journal of Gynaecological Oncology, 2016, 37(4): 488-492.
[15] K. Chikazawa, S. Netsu, R. Konno. Outcomes of concurrent radiotherapy and weekly paclitaxel/carboplatin therapy in cervical cancer: a retrospective study[J]. European Journal of Gynaecological Oncology, 2016, 37(4): 511-516.
No Suggested Reading articles found!